Possible scenarios for how antitumor function of nonalloreactive γδ T cells could be exploited after HCT. Aminobisphosphonates in combination with IL-2 or the application of therapeutic monoclonal antibodies can activate γδ T cells in vivo. By using TCRαβ-depleted grafts, large numbers of γδ T cells are coinfused. γδ T cells and their subsets either from patients or from their donors can be expanded ex vivo and manipulated prior to adoptive transfer into the patients.